Efficacy and adverse events of immune checkpoint inhibitors in esophageal cancer patients: Challenges and perspectives for immunotherapy
Esophageal cancer (EC) is the seventh most common cancer worldwide. Patients with EC have a generally poor prognosis mainly due to the lack of effective treatments. Cancer immunotherapy is a promising novel treatment option for EC. This literature review investigated the clinical efficacy of immunot...
Gespeichert in:
| Veröffentlicht in: | Asia-Pacific journal of clinical oncology 2024-04, Vol.20 (2), p.180-187 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 187 |
|---|---|
| container_issue | 2 |
| container_start_page | 180 |
| container_title | Asia-Pacific journal of clinical oncology |
| container_volume | 20 |
| creator | Ma, Yingjie Yu, Junxian Ma, Xiaoting Li, Qin Su, Qiang Cao, Bangwei |
| description | Esophageal cancer (EC) is the seventh most common cancer worldwide. Patients with EC have a generally poor prognosis mainly due to the lack of effective treatments. Cancer immunotherapy is a promising novel treatment option for EC. This literature review investigated the clinical efficacy of immunotherapy either alone or in combination with chemotherapy or targeted therapy. In addition, we analyzed the adverse events associated with immune checkpoint inhibitors (ICIs). In conclusion, ICIs increase the efficacy of EC treatments, thereby improving the outcomes of EC patients. The findings of this study may help enhance the response to immunotherapy, diminish toxicity, and thus eventually improve medical care for patients with EC. |
| doi_str_mv | 10.1111/ajco.13961 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2813567116</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2813567116</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3931-d8784c084b34d62e9cfc628f8b365c5fa5d1f788f0eab3f5d75c75adb11889603</originalsourceid><addsrcrecordid>eNp9kc9u1DAQhy0Eon_gwgMgS1wQ0hZPHMcOt2pVCqhSL3C2HGfceEniYCdb7Rvw2Hib0gMH5jKj0TefRvoR8gbYBeT6aHY2XACvK3hGTkGWfCNFxZ8_zUKckLOUdozxuqjhJTnhEiQwrk7J7yvnvDX2QM3YUtPuMSakuMdxTjQ46odhGZHaDu3PKfhxpn7sfOPnEFMeKaYwdeYOTU-tGS1GOpnZH68_0W1n-h7HO0wP8imrJ7Sz3-eFC3F1h7nDaKbDK_LCmT7h68d-Tn58vvq-_bK5ub3-ur282Vhec9i0SqrSMlU2vGyrAmvrbFUopxpeCSucES04qZRjaBruRCuFlcK0DYBSdcX4OXm_eqcYfi2YZj34ZLHvzYhhSbpQwEUlAaqMvvsH3YUljvk7zVnBJAPJykx9WCkbQ0oRnZ6iH0w8aGD6mI8-5qMf8snw20fl0gzYPqF_A8kArMC97_HwH5W-_La9XaV_AO6KnRs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3020701704</pqid></control><display><type>article</type><title>Efficacy and adverse events of immune checkpoint inhibitors in esophageal cancer patients: Challenges and perspectives for immunotherapy</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Ma, Yingjie ; Yu, Junxian ; Ma, Xiaoting ; Li, Qin ; Su, Qiang ; Cao, Bangwei</creator><creatorcontrib>Ma, Yingjie ; Yu, Junxian ; Ma, Xiaoting ; Li, Qin ; Su, Qiang ; Cao, Bangwei</creatorcontrib><description>Esophageal cancer (EC) is the seventh most common cancer worldwide. Patients with EC have a generally poor prognosis mainly due to the lack of effective treatments. Cancer immunotherapy is a promising novel treatment option for EC. This literature review investigated the clinical efficacy of immunotherapy either alone or in combination with chemotherapy or targeted therapy. In addition, we analyzed the adverse events associated with immune checkpoint inhibitors (ICIs). In conclusion, ICIs increase the efficacy of EC treatments, thereby improving the outcomes of EC patients. The findings of this study may help enhance the response to immunotherapy, diminish toxicity, and thus eventually improve medical care for patients with EC.</description><identifier>ISSN: 1743-7555</identifier><identifier>EISSN: 1743-7563</identifier><identifier>DOI: 10.1111/ajco.13961</identifier><identifier>PMID: 37171038</identifier><language>eng</language><publisher>Australia: Wiley Subscription Services, Inc</publisher><subject>adverse effects ; Adverse events ; Cancer ; Cancer immunotherapy ; Chemotherapy ; esophageal cancer ; Esophageal Neoplasms - drug therapy ; Humans ; Immune checkpoint inhibitors ; Immune Checkpoint Inhibitors - adverse effects ; immunotherapy ; Immunotherapy - adverse effects ; Literature reviews ; Patients ; prognosis ; Toxicity</subject><ispartof>Asia-Pacific journal of clinical oncology, 2024-04, Vol.20 (2), p.180-187</ispartof><rights>2023 John Wiley & Sons Australia, Ltd.</rights><rights>2024 John Wiley & Sons Australia, Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3931-d8784c084b34d62e9cfc628f8b365c5fa5d1f788f0eab3f5d75c75adb11889603</citedby><cites>FETCH-LOGICAL-c3931-d8784c084b34d62e9cfc628f8b365c5fa5d1f788f0eab3f5d75c75adb11889603</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fajco.13961$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fajco.13961$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37171038$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ma, Yingjie</creatorcontrib><creatorcontrib>Yu, Junxian</creatorcontrib><creatorcontrib>Ma, Xiaoting</creatorcontrib><creatorcontrib>Li, Qin</creatorcontrib><creatorcontrib>Su, Qiang</creatorcontrib><creatorcontrib>Cao, Bangwei</creatorcontrib><title>Efficacy and adverse events of immune checkpoint inhibitors in esophageal cancer patients: Challenges and perspectives for immunotherapy</title><title>Asia-Pacific journal of clinical oncology</title><addtitle>Asia Pac J Clin Oncol</addtitle><description>Esophageal cancer (EC) is the seventh most common cancer worldwide. Patients with EC have a generally poor prognosis mainly due to the lack of effective treatments. Cancer immunotherapy is a promising novel treatment option for EC. This literature review investigated the clinical efficacy of immunotherapy either alone or in combination with chemotherapy or targeted therapy. In addition, we analyzed the adverse events associated with immune checkpoint inhibitors (ICIs). In conclusion, ICIs increase the efficacy of EC treatments, thereby improving the outcomes of EC patients. The findings of this study may help enhance the response to immunotherapy, diminish toxicity, and thus eventually improve medical care for patients with EC.</description><subject>adverse effects</subject><subject>Adverse events</subject><subject>Cancer</subject><subject>Cancer immunotherapy</subject><subject>Chemotherapy</subject><subject>esophageal cancer</subject><subject>Esophageal Neoplasms - drug therapy</subject><subject>Humans</subject><subject>Immune checkpoint inhibitors</subject><subject>Immune Checkpoint Inhibitors - adverse effects</subject><subject>immunotherapy</subject><subject>Immunotherapy - adverse effects</subject><subject>Literature reviews</subject><subject>Patients</subject><subject>prognosis</subject><subject>Toxicity</subject><issn>1743-7555</issn><issn>1743-7563</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc9u1DAQhy0Eon_gwgMgS1wQ0hZPHMcOt2pVCqhSL3C2HGfceEniYCdb7Rvw2Hib0gMH5jKj0TefRvoR8gbYBeT6aHY2XACvK3hGTkGWfCNFxZ8_zUKckLOUdozxuqjhJTnhEiQwrk7J7yvnvDX2QM3YUtPuMSakuMdxTjQ46odhGZHaDu3PKfhxpn7sfOPnEFMeKaYwdeYOTU-tGS1GOpnZH68_0W1n-h7HO0wP8imrJ7Sz3-eFC3F1h7nDaKbDK_LCmT7h68d-Tn58vvq-_bK5ub3-ur282Vhec9i0SqrSMlU2vGyrAmvrbFUopxpeCSucES04qZRjaBruRCuFlcK0DYBSdcX4OXm_eqcYfi2YZj34ZLHvzYhhSbpQwEUlAaqMvvsH3YUljvk7zVnBJAPJykx9WCkbQ0oRnZ6iH0w8aGD6mI8-5qMf8snw20fl0gzYPqF_A8kArMC97_HwH5W-_La9XaV_AO6KnRs</recordid><startdate>202404</startdate><enddate>202404</enddate><creator>Ma, Yingjie</creator><creator>Yu, Junxian</creator><creator>Ma, Xiaoting</creator><creator>Li, Qin</creator><creator>Su, Qiang</creator><creator>Cao, Bangwei</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>202404</creationdate><title>Efficacy and adverse events of immune checkpoint inhibitors in esophageal cancer patients: Challenges and perspectives for immunotherapy</title><author>Ma, Yingjie ; Yu, Junxian ; Ma, Xiaoting ; Li, Qin ; Su, Qiang ; Cao, Bangwei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3931-d8784c084b34d62e9cfc628f8b365c5fa5d1f788f0eab3f5d75c75adb11889603</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>adverse effects</topic><topic>Adverse events</topic><topic>Cancer</topic><topic>Cancer immunotherapy</topic><topic>Chemotherapy</topic><topic>esophageal cancer</topic><topic>Esophageal Neoplasms - drug therapy</topic><topic>Humans</topic><topic>Immune checkpoint inhibitors</topic><topic>Immune Checkpoint Inhibitors - adverse effects</topic><topic>immunotherapy</topic><topic>Immunotherapy - adverse effects</topic><topic>Literature reviews</topic><topic>Patients</topic><topic>prognosis</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ma, Yingjie</creatorcontrib><creatorcontrib>Yu, Junxian</creatorcontrib><creatorcontrib>Ma, Xiaoting</creatorcontrib><creatorcontrib>Li, Qin</creatorcontrib><creatorcontrib>Su, Qiang</creatorcontrib><creatorcontrib>Cao, Bangwei</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Asia-Pacific journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ma, Yingjie</au><au>Yu, Junxian</au><au>Ma, Xiaoting</au><au>Li, Qin</au><au>Su, Qiang</au><au>Cao, Bangwei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and adverse events of immune checkpoint inhibitors in esophageal cancer patients: Challenges and perspectives for immunotherapy</atitle><jtitle>Asia-Pacific journal of clinical oncology</jtitle><addtitle>Asia Pac J Clin Oncol</addtitle><date>2024-04</date><risdate>2024</risdate><volume>20</volume><issue>2</issue><spage>180</spage><epage>187</epage><pages>180-187</pages><issn>1743-7555</issn><eissn>1743-7563</eissn><abstract>Esophageal cancer (EC) is the seventh most common cancer worldwide. Patients with EC have a generally poor prognosis mainly due to the lack of effective treatments. Cancer immunotherapy is a promising novel treatment option for EC. This literature review investigated the clinical efficacy of immunotherapy either alone or in combination with chemotherapy or targeted therapy. In addition, we analyzed the adverse events associated with immune checkpoint inhibitors (ICIs). In conclusion, ICIs increase the efficacy of EC treatments, thereby improving the outcomes of EC patients. The findings of this study may help enhance the response to immunotherapy, diminish toxicity, and thus eventually improve medical care for patients with EC.</abstract><cop>Australia</cop><pub>Wiley Subscription Services, Inc</pub><pmid>37171038</pmid><doi>10.1111/ajco.13961</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1743-7555 |
| ispartof | Asia-Pacific journal of clinical oncology, 2024-04, Vol.20 (2), p.180-187 |
| issn | 1743-7555 1743-7563 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2813567116 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | adverse effects Adverse events Cancer Cancer immunotherapy Chemotherapy esophageal cancer Esophageal Neoplasms - drug therapy Humans Immune checkpoint inhibitors Immune Checkpoint Inhibitors - adverse effects immunotherapy Immunotherapy - adverse effects Literature reviews Patients prognosis Toxicity |
| title | Efficacy and adverse events of immune checkpoint inhibitors in esophageal cancer patients: Challenges and perspectives for immunotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T23%3A49%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20adverse%20events%20of%20immune%20checkpoint%20inhibitors%20in%20esophageal%20cancer%20patients:%20Challenges%20and%20perspectives%20for%20immunotherapy&rft.jtitle=Asia-Pacific%20journal%20of%20clinical%20oncology&rft.au=Ma,%20Yingjie&rft.date=2024-04&rft.volume=20&rft.issue=2&rft.spage=180&rft.epage=187&rft.pages=180-187&rft.issn=1743-7555&rft.eissn=1743-7563&rft_id=info:doi/10.1111/ajco.13961&rft_dat=%3Cproquest_cross%3E2813567116%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3020701704&rft_id=info:pmid/37171038&rfr_iscdi=true |